¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"myocardial lead"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • silent myocardial infarction
    ¹«Áõ»ó½É±Ù°æ»öÁõ
  • bipolar lead
    µÎ±ØÀ¯µµ, ½Ö±ØÀ¯µµ
  • black lead
    Èæ¿¬
  • electrocardiogram lead
    ½ÉÀüµµÀ¯µµ
  • endocardial lead
    ½É³»¸·À¯µµ, ½ÉÀå¼Ó¸·À¯µµ
  • epicardial lead
    ½É¿Ü¸·À¯µµ, ½ÉÀå¹Ù±ù¸·À¯µµ
  • esophageal lead
    ½ÄµµÀ¯µµ
  • lead
    1. ³³ 2. µµÃâ, À¯µµ 3. Àü±Ø
  • lead acetate
    Ãʻ곳
  • lead colic
    ³³±ÞÅëÁõ
  • lead encephalopathy
    ³³Áßµ¶³úº´(Áõ)
  • lead gout
    ³³Åëdz
  • lead line
    ³³¼±
  • lead neuritis
    ³³Áßµ¶½Å°æº´Áõ
  • lead neuropathy
    ³³Áßµ¶½Å°æº´(Áõ)
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • myocardial siderosis
    ½ÉÀå±ÙÀ°Ã¶Ä§ÂøÁõ
  • myocardial stimulant
    ½É±ÙÀÚ±ØÁ¦, °­½ÉÁ¦
  • myocardial perfusion scintigraphy
    ½É±ÙÁÖ»ç¼ú, ½ÉÀå±ÙÀ°¼¶±¤Á¶¿µ¼ú
  • black lead
    Èæ¿¬
  • lead-time bias
    Á¶±â¹ß°ß±â°£¹ÙÀ̾
  • lead colic
    ³³±ÞÅëÁõ
  • electrocardiogram lead
    ½ÉÀüµµÀ¯µµ
  • endocardial lead
    ½É³»¸·À¯µµ
  • epicardial lead
    ½ÉÀå¿Ü¸·À¯µµ
  • esophageal lead
    ½ÄµµÀ¯µµ
  • lead pipe fracture
    ³³ÆÄÀÌÇÁ°ñÀý, ¿¬°ü»ó°ñÀý
  • lead gout
    ³³Åëdz
  • lead
    ³³, µµÃâ, À¯µµ
  • lead acetate
    Ãʻ곳
  • lead nitrate
    Áú»ê³³
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • myocardial damage
    ½É±ÙÀå¾Ö, ½É±Ù¼Õ»ó(¡­áßß¿).
  • myocardial degeneration
    ½É±Ùº¯¼º(¡­Ü¨àõ).
  • myocardial degeneration
    ½É±Ùº¯¼º(ãýÐÉܨàõ)
  • myocardial depressant
    ½É(±Ù)¾ïÁ¦¾à(¡­åäð¤å·), ½É±Ù¾ïÁ¦Á¦.
  • myocardial depressant
    ½É±Ù¾ïÁ¦Á¦, ½É(±Ù)¾ïÁ¦¾à(¡­åäð¤å·).
  • myocardial depressant factor
    ½É±Ù¾ïÁ¦ÀÎÀÚ.
  • myocardial depression
    ½É±Ù¾ïÁ¦
  • myocardial disease
    ½É±ÙÁúȯ(¡­òðü´).
  • myocardial disease
    ½É±ÙÁúȯ(¡­òðü´)
  • myocardial failure
    ½É±ÙºÎÀü(¡­ÝÕîï).
  • myocardial fibrosis
    ½É±Ù¼¶À¯Áõ(¡­àéë«ñø).
  • myocardial function
    ½É±Ù±â´É.
  • myocardial hypoxia
    ½É±ÙÀú»ê¼ÒÁõ(ãýÐÉî¸ß«áÈñø).
  • myocardial infarction
    ½É±Ù°æ»öÁõ(¡­ÌÛßáñø).
  • myocardial infarction
    ½É±Ù°æ»öÁõ(¡­ÌÛßáñø)
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
PMI pain management inventory; past medical illness; patient medication instruction; perioperative myoca...
SMI Self-Motivation Inventory; senior medical investigator; severe mental impairment; silent myocardial ...
TAMI thrombolysis and angioplasty in myocardial infarction; transmural anterior myocardial infarction
TIMI trhombolysis in myocardial infarction; transmural inferior myocardial infarction
TMI testing motor impairment; threatened myocardial infarction; transmural myocardial infarction
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 2
AMI Acute myocardial infarct
AMI Anterior myocardial infarction
CK-MB Creatine kinase-myocardial band
DMI Doppler Myocardial Imaging
MB Myocardial Bridge
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • endocardial lead
    ½É³»¸· À¯µµ
  • lead acetate
    ÃÊ»ê ³³
  • lead anemia
    ¿¬ ºóÇ÷
    ³³¿¡ ÀÇÇÏ¿© ¹ß»ýÇÏ´Â ºóÇ÷.
  • lead borosilicate
    ºØ±Ô»ê ³³
  • lead chromate
    Å©·Ò»ê ³³
  • lead dichloride
    ÀÌ¿°È­ ³³
  • lead equivalent
    ¿¬ ´ç·®
    ¹æ»ç¼± Â÷Æó¿¡ À־ ¾î¶² ¹°ÁúÀÇ Â÷Æó È¿°ú¸¦ ±×¿Í ºñ½ÁÇÑ È¿°ú¸¦ ³ªÅ¸³»´Â ³³ÀÇ µÎ²²·Î Ç¥ÇöÇÑ °Í.
  • lead glass
    ³³ À¯¸®
    X¼± ÃÔ¿µ ½Ã 1Â÷¼±À̳ª 2Â÷¼±À¸·ÎºÎÅÍ º¸È£¹Þ±â À§ÇÏ¿© ¹æ¾î¸· ¶Ç´Â ¹æ¾îº®ÀÇ Ã¢¹®¿¡ ÀåÄ¡ÇÏ´Â À¯¸®·Î, ±× ¾È¿¡ ³³ÀÌ µé¾î ÀÖ´Â °Í.
  • lead gray
    ³³ ȸ»ö
  • lead line
    ¿¬¼±
    ³³ÀÌ ´Ù¸¥ ±Ý¼Ó ȤÀº °°Àº ³²°ú ÁßÇÕµÇ¾î »ý±ä ¼±.
  • lead neuritis
    ¿¬ ½Å°æ¿°
  • lead nitrate
    Áú»ê ³³
  • lead oleate ointment
    ´Ü¿¬ ¿¬°í
  • lead orthoplumbate
    ¿À¸£Åä³³»ê ³³
  • lead paper
    ¿¬´çÁö
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 2
myocardial insufficiency A condition where there is ineffective pumping of the heart leading to an accumulation of fluid in the lungs. Typical symptoms include shortness of breath with exertion, difficulty breathing when lying flat and leg or ankle swelling. Causes include chronic hypertension, cardiomyopathy and myocardial infarction.
(27 Sep 1997)
myocardial ischemia A disorder of cardiac function caused by insufficient blood flow to the muscle tissue of the heart. The decreased blood flow may be due to narrowing of the coronary arteries (coronary arteriosclerosis), to obstruction by a thrombus (coronary thrombosis), or less commonly, to diffuse narrowing of arterioles and other small vessels within the heart. Severe interruption of the blood supply to the myocardial tissue may result in necrosis of cardiac muscle (myocardial infarction).
(12 Dec 1998)
myocardial necrosis Irreversible destruction of myocardial (heart muscle) cells.
(27 Sep 1997)
myocardial perfusion imaging <radiology> (thallium scanning) thallium (Tl) 201, acts as potassium analog, dose 2.0 - 3.0 mCi at peak exercise, 4% of injected dose reaches myocardium, imaging: exercise (1-5 min), redistribution (3-4 hrs), views: anterior, LAO 45', left lateral, interpretation: normal, reversible abnormalitymost likely to be exercise-induced ischemia, nonreversible abnormalitymost likely to be prior myocardial infarction, reverse redistribution most likely to be normal areas wash out faster, lung activity most likely to be LV failure during exercise see also: dipyridamole test, nuclear cardiology
(12 Dec 1998)
myocardial reperfusion Generally, restoration of blood supply to heart tissue which is ischemic due to decrease in normal blood supply. The decrease may result from any source including atherosclerotic obstruction, narrowing of the artery, or surgical clamping. Reperfusion can be induced to treat ischemia. Methods include chemical dissolution of an occluding thrombus, administration of vasodilator drugs, angioplasty, catheterization, and artery bypass graft surgery. However, it is thought that reperfusion can itself further damage the ischemic tissue, causing myocardial reperfusion injury.
(12 Dec 1998)
myocardial reperfusion injury Functional, metabolic, or structural changes in ischemic heart muscle thought to result from reperfusion to the ischemic areas. Changes can be fatal to muscle cells and may include oedema with explosive cell swelling and disintegration, sarcolemma disruption, fragmentation of mitochondria, contraction band necrosis, enzyme washout, and calcium overload. Other damage may include haemorrhage and ventricular arrhythmias. One possible mechanism of damage is thought to be oxygen free radicals. Treatment currently includes the introduction of scavengers of oxygen free radicals, and injury is thought to be prevented by warm blood cardioplegic infusion prior to reperfusion.
(12 Dec 1998)
myocardial revascularization The restoration of blood supply to the myocardium.
(12 Dec 1998)
myocardial rigor mortis Irreversible contraction of the left ventricle of the heart as a complication seen in the early period of cardiopulmonary bypass and now avoided by appropriate cardioplegic solutions.
Synonym: myocardial rigor mortis, stone heart.
(05 Mar 2000)
myocardial stunning Prolonged dysfunction of the myocardium after a brief episode of severe ischemia, with gradual return of contractile activity. It occurs frequently, both in the experimental laboratory and in clinical medicine. Since stunned myocardium occurs adjacent to necrotic tissue after prolonged coronary occlusion, many myocardial infarcts may be a mixture of necrotic and stunned tissue.
(12 Dec 1998)
posterior myocardial infarction Infarction involving the posterior wall of the heart; also formerly used erroneously of infarction's involving the inferior or diaphragmatic surface of the heart.
(05 Mar 2000)
silent myocardial infarction Infarction that produces none of the characteristic symptoms and signs of myocardial infarction.
(05 Mar 2000)
subendocardial myocardial infarction Infarction that involves only the layer of muscle subjacent to the endocardium.
(05 Mar 2000)
nontransmural myocardial infarction Necrosis of heart muscle that fails to extend from the endocardium to the epicardium, often erroneously considered relatively benign.
(05 Mar 2000)
diaphragmatic myocardial infarction Infarction in which the inferior or diaphragmatic wall of the heart is involved, producing indicative changes in leads II, III, and aVF in the electrocardiogram.
Synonym: diaphragmatic myocardial infarction.
(05 Mar 2000)
inferior myocardial infarction Infarction in which the inferior or diaphragmatic wall of the heart is involved, producing indicative changes in leads II, III, and aVF in the electrocardiogram.
Synonym: diaphragmatic myocardial infarction.
(05 Mar 2000)
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 10 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
  • lead poisoning
    ¿¬µ¶;³³Áßµ¶
  • lead swinger
    ²ÒÀïÀÌ;°ÔÀ¸¸§¹ðÀÌ(Ãø¿¬ ÀÛ¾÷À» Çϴ üÇÏ´Â)
  • lead time
    ±âȹ¿¡¼­ »ý»ê±îÁöÀÇ ½Ã°£;¹ßÁÖ¿¡¼­ ¹è´Þ±îÁöÀÇ ½Ã°£;¹ßÁÖ¿¡¼­ ¹è´Þ±îÁöÀÇ ½Ã°£
  • lead wool
    ¿¬¸ð(ÆÄÀÌÇÁ Á¢ÇÕ¿ë)
  • pot lead
    Èæ¿¬
  • red lead
    ¿¬´Ü;±¤¸í´Ü(»êÈ­³³À¸·Î ¸¸µç ¹°°¨)
  • red-lead
    ¿¬´Ü(±¤¸í´Ü)À» ¹Ù¸£´Ù
  • sounding lead
    Ãø¿¬
  • tetraethyl lead
    Åׯ®¶ó¿¡Æ¿¿¬;4¿¡Æ¿¿¬
  • white lead
    ¹é¿¬
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 2
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 2
ÅëÇÕ°Ë»ö ¿Ï·á